Sanofi and Cipla Announce Distribution Partnership for CNS Products in India

Sanofi India and Cipla Limited have announced an exclusive partnership for the distribution and promotion of Sanofi's Central Nervous System (CNS) product range within India. Under the agreement, Cipla will take responsibility for distributing Sanofi's six CNS brands, including the anti-epileptic medication Frisium®.

Sanofi India will retain ownership, import, and manufacturing responsibilities for its complete CNS product line at its facilities in India and internationally. Cipla will leverage its extensive nationwide network, including its sales professionals, distributors, and institutional reach, to expand access to these treatments for patients across India.

The partnership aims to significantly enhance the availability of Sanofi's established CNS treatments, which already benefit numerous patients in urban areas. Cipla's broad market presence is expected to facilitate wider access to healthcare professionals and patients throughout the country.

Sanofi India has been operating in India for nearly seven decades, focusing on accelerating its innovation pipeline in areas such as diabetes, rare diseases, and vaccines. Cipla is a global pharmaceutical company with a strong focus on complex generics and has expertise in therapeutic areas including CNS.